OncoCardia

Curated by Signal

Provider of AI and stem cell technology to design efficacious cancer therapeutics

Overview

Provider of AI and stem cell technology to design efficacious cancer therapeutics. The company's platform uses AI to predict safer drug analogues and their synthesis routes forthe drug discovery process. It aims to improve patient outcomes and reduce the risk of cardiac toxicity associated with cancer treatment.

Key facts

Founded: 2023
Headquarters: Philadelphia, United States
Stage: Sign up to view
Industry: Health Technology

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Health Technology companies

Count.It
Platform connecting wearable tracking devices and apps for virtual wellness challenges
Health TechnologyNew York City, United States
BeneFit
Reward based fitness tracking
Health TechnologyNew Orleans, United States
Dexzyle
Cloud based platform offering healthcare communication and engagement app
Health TechnologyDenver, United States

About OncoCardia

What does OncoCardia do?

Provider of AI and stem cell technology to design efficacious cancer therapeutics.

Where is OncoCardia headquartered?

OncoCardia is headquartered in Philadelphia, United States.

When was OncoCardia founded?

OncoCardia was founded in 2023.

Which sector is OncoCardia in?

OncoCardia operates in Health Technology.

Who are OncoCardia's competitors?

Companies similar to OncoCardia include Count.It, BeneFit, and Dexzyle.